Skip to main content
Evidence Snapshot

D2-like dopamine receptor

CHEMBL2331075 PROTEIN FAMILY Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:53Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2331075
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats D2-like dopamine receptor as ChEMBL target CHEMBL2331075, mapped to UniProt P14416. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
D2-like dopamine receptor
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2331075
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P14416
D(2) dopamine receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why D2-like dopamine receptor matters

As of 2026-09-13

D2-like dopamine receptor is reviewed as D(2) dopamine receptor (UniProt P14416); D2-like dopamine receptor shows approved-linked disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block.; 11 linked drugs keep this evidence frame grounded..

Protein context
D(2) dopamine receptor

D(2) dopamine receptor Sequence length is 443 aa.

Review this target as D2-like dopamine receptor, mapped to UniProt P14416. ChEMBL maps the protein component as D(2) dopamine receptor. Sequence length is 443 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P14416 Protein
Disease context
schizophrenia

D2-like dopamine receptor shows approved-linked disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CHLORPROMAZINE, HALOPERIDOL, HALOPERIDOL DECANOATE.

Start review with schizophrenia because it currently carries approved-linked support. Linked drugs include CHLORPROMAZINE, HALOPERIDOL, HALOPERIDOL DECANOATE, HALOPERIDOL LACTATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 11 linked drugs
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why D2-like dopamine receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P14416, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why schizophrenia is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

0
Total Compounds
0
Total Assays
0
Approved Drugs
-
Activity Types

pChEMBL Activity Distribution

← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:53Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2331075